Gilead Sciences Inc. (NASDAQ:GILD) – Research analysts at Leerink Swann lowered their Q3 2016 earnings estimates for Gilead Sciences in a report released on Friday. Leerink Swann analyst G. Porges now forecasts that the firm will earn $2.81 per share for the quarter, down from their prior estimate of $2.91. Leerink Swann has a “Outperform” rating and a $112.00 price target on the stock.

A number of other research analysts also recently weighed in on the company. Jefferies Group raised their price objective on Gilead Sciences from $91.00 to $93.00 and gave the company a “buy” rating in a research note on Wednesday, October 5th. Piper Jaffray Cos. reissued a “buy” rating and issued a $108.00 price objective on shares of Gilead Sciences in a research note on Monday, August 15th. Morgan Stanley reissued a “hold” rating and issued a $103.00 price objective on shares of Gilead Sciences in a research note on Wednesday, June 15th. Berenberg Bank initiated coverage on Gilead Sciences in a research note on Thursday, September 22nd. They issued a “buy” rating on the stock. Finally, Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research note on Sunday, July 10th. Ten investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $104.71.

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) opened at 75.49 on Monday. The company has a market capitalization of $99.62 billion, a PE ratio of 6.63 and a beta of 1.10. Gilead Sciences has a 52 week low of $74.92 and a 52 week high of $111.11. The company’s 50-day moving average price is $78.79 and its 200 day moving average price is $84.83.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The firm had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. During the same period last year, the business posted $3.15 earnings per share. The firm’s revenue for the quarter was down 5.7% on a year-over-year basis.

A number of hedge funds and other institutional investors have recently bought and sold shares of GILD. CWM LLC boosted its position in Gilead Sciences by 0.6% in the second quarter. CWM LLC now owns 2,957 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 17 shares in the last quarter. Cadence Bank NA boosted its position in Gilead Sciences by 0.8% in the second quarter. Cadence Bank NA now owns 3,727 shares of the biopharmaceutical company’s stock valued at $311,000 after buying an additional 28 shares in the last quarter. Marble Harbor Investment Counsel LLC boosted its position in Gilead Sciences by 0.9% in the second quarter. Marble Harbor Investment Counsel LLC now owns 3,330 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 30 shares in the last quarter. Birch Hill Investment Advisors LLC boosted its position in Gilead Sciences by 0.9% in the second quarter. Birch Hill Investment Advisors LLC now owns 3,336 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 30 shares in the last quarter. Finally, West Oak Capital LLC boosted its position in Gilead Sciences by 0.7% in the third quarter. West Oak Capital LLC now owns 4,449 shares of the biopharmaceutical company’s stock valued at $352,000 after buying an additional 32 shares in the last quarter. 77.93% of the stock is owned by hedge funds and other institutional investors.

In other Gilead Sciences news, insider John C. Martin sold 100,000 shares of the business’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $77.63, for a total value of $7,763,000.00. Following the completion of the transaction, the insider now directly owns 3,231,096 shares of the company’s stock, valued at $250,829,982.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Kevin E. Lofton sold 3,500 shares of the business’s stock in a transaction dated Wednesday, August 24th. The shares were sold at an average price of $81.97, for a total value of $286,895.00. The disclosure for this sale can be found here. 1.40% of the stock is owned by company insiders.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were paid a $0.47 dividend. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a yield of 2.49%. Gilead Sciences’s payout ratio is 16.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.